Research on personalized medicines is gaining popularity in the cancer research industry, which has increased the need for effective and reliable diagnostic procedures and is expected to drive the growth of the whole slide imaging systems market. Growing demand for laboratory diagnosis procedures is also expected to fuel future growth, according to a new report from Persistence Market Research.

Henry Ford Cancer Institute is first-in-the-world to enroll a glioblastoma patient in the GBM AGILE Trial (Adaptive Global Innovative Learning Environment). The novel trial design and architecture is made possible by an international collaboration of experts in the care of patients with glioblastoma and the design of clinical trials. Led by the trial sponsor Global Coalition for Adaptive Research (GCAR), GBM AGILE is a seamless Phase II (Efficacy and Safety)/Phase III (Confirmatory) trial aimed at identifying the most effective therapies for patients with glioblastoma, the most aggressive form of brain cancer.